|
Shetty K, Timmins K, Brensinger C, Furth EE, Rattan S, Sun W, Rosen M, Soulen M, Shaked A, Reddy KR, Olthoff KM. Liver transplantation for hepatocellular carcinoma validation of present selection criteria in predicting outcome
Liver Transpl
Vertonese ML, Stevenson JP, Sun W, Redlinger M, Algazy K, Giantonio B, Hahn S Vaughn D, Thorn C, Whitehead AS, Haller D, O’Dwyer PJ. Phase I trial of UFT/leucovorin in patients with advanced cancer
Euro J Cancer
Stevenson JP, Rosen M, Sun W, Gallagher M, Haller DG, Vaughn D, Giantoio B, Zimmer R, Petros W, Stratford M, Chaplin D, Young SL, Schnall M, O’Dwyer PJ: Phase I trial of the antivascular agent combretastain A4 phosephate on a five-day schedule to patients with cancer: MRI evidence for altered tumor blood flow
J Clin Oncol
Sun W, Stevenson JP, Gallagher M, Vaughn D, Hahn SM, Haller DG, Gallant G, and O’Dwyer PJ. Phase I and pharmacokinetic trial of BMS-184476 administered as a 1-hour intravenous infusion in combination with cisplatin every 21 days
Clin Cancer Res
Flaherty KT, Stevenson JP, Gallagher M, Algazy KM, Sun W, Haller DG, O’Dwyer PJ. Dose escalation study of tezacitabine in combination with cisplatin in patients with advanced cancer
Cancer
Sun W, Haller D. Irinotecan and fixed-dose rate gemcitabine in advanced pancreatic and biliary cancer: Phase I study
Oncology
Stevenson JP, Sun W, Gallagher M, Johnson R, Vaughn D, Schuchter L, Alazy K, Hahn S, Enas N, Ellis D, Thornton D, and O’Dwyer PJ. Phase I trial of the cryptophycin analogue LY 355703 administered as an intravenous infusion on a day and 8 schedule every 21 days
Clin Cancer Res
Sun W, Stevenson JP, Gallo JM, Redlinger M, Haller DG, Algazy K, Giantonio B, Alila H, and O’Dwyer PJ. Phase I and pharmacokinetic trail of the proapoptotic sulindac analog CP-461 in patients with advanced cancer
Clin Cancer Res
Dr. Weijing Sun
Dirección profesional:
16 Penn Tower, 3400 Spruce Street, University of Pennsylvania Cancer Center, Philadelphia, PA 19104 USA
|
